Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
GlycoMimetics' Upro swiftly advancing in China, says Roth Capital » 10:14
09/27/21
09/27
10:14
09/27/21
10:14
GLYC

GlycoMimetics

$2.34 /

+0.055 (+2.41%)

Roth Capital analyst…

Roth Capital analyst Zegbeh Jallah hosted a call with Sanjeev Redkar, co-founder, Executive Director, and President of Apollomics, to discuss their decision to in-license GlycoMimetics' Uproleselan/APL-106 for development in Greater China for AML and other heme malignancies. The analyst was "very encouraged" by Apollomics and Sanjeev's enthusiasm around Uproleselan's development in Greater China. If nothing else, the conversation cemented the analyst's convictions around Uproleselan's broad appeal and potential in AML and other Heme malignancies. It was also evident that the intent is to swiftly advance Upro through the clinic as he noted that he hopes to transition the ongoing Phase 1 study into a Phase 3 study by year-end, which would be quite impressive, Jallah adds. The analyst has a Buy rating and a price target of $15 on GlycoMimetics' shares.

ShowHide Related Items >><<
GLYC GlycoMimetics
$2.34 /

+0.055 (+2.41%)

GLYC GlycoMimetics
$2.34 /

+0.055 (+2.41%)

07/12/21 Roth Capital
GlycoMimetics testing Upro + VenAza combo in AML, says Roth Capital
05/03/21 Stifel
GlycoMimetics price target lowered to $8 from $9 at Stifel
03/02/21 Roth Capital
GlycoMimetics has near-term opportunity with Uproleselan, says Roth Captial
12/08/20 Roth Capital
GlycoMimetics price target raised to $15 from $9 at Roth Capital
GLYC GlycoMimetics
$2.34 /

+0.055 (+2.41%)

Hot Stocks
GlycoMimetics to study uproleselan in patients with COVID-19 pneumonia » 09:40
09/27/21
09/27
09:40
09/27/21
09:40
GLYC

GlycoMimetics

$2.28 /

+ (+0.00%)

The ClinicalTrials.gov…

The ClinicalTrials.gov website shows in a post dated September 27 that sponsor Lena Napolitano, MD, and collaborator GlycoMimetics plan a study to find out whether the drug uproleselan can help patients with severe COVID-19 pneumonia. "Investigators will study both the side effects of the drug and assess if the drug will help patients recover more quickly and slow down the progression of acute respiratory failure," the post stated. Reference Link

ShowHide Related Items >><<
GLYC GlycoMimetics
$2.28 /

+ (+0.00%)

GLYC GlycoMimetics
$2.28 /

+ (+0.00%)

07/12/21 Roth Capital
GlycoMimetics testing Upro + VenAza combo in AML, says Roth Capital
05/03/21 Stifel
GlycoMimetics price target lowered to $8 from $9 at Stifel
03/02/21 Roth Capital
GlycoMimetics has near-term opportunity with Uproleselan, says Roth Captial
12/08/20 Roth Capital
GlycoMimetics price target raised to $15 from $9 at Roth Capital
GLYC GlycoMimetics
$2.28 /

+ (+0.00%)

Hot Stocks
Journal BLOOD publishes efficacy and safety data for GlycoMimetics' uproleselan » 16:02
09/23/21
09/23
16:02
09/23/21
16:02
GLYC

GlycoMimetics

$2.29 /

+0.07 (+3.15%)

The company states:…

The company states: "Efficacy and safety data from a Phase 1/2 clinical study of uproleselan, GlycoMimetics' lead investigational drug, were published online September 16, 2021 in the journal BLOOD. In the manuscript, scientists highlight an analysis of minimal residual disease and report an MRD negative rate of 69% in trial participants with relapsed/refractory acute myeloid leukemia, indicating an enhanced depth of response following addition of uproleselan to salvage therapy. The paper also confirms that uproleselan can be safely combined with an intensive salvage chemotherapy regimen without adding toxicity in both relapsed/refractory and in newly diagnosed older AML patients and builds upon results first reported at the 2018 ASH Meeting." Chief Medical Officer Eric J. Feldman said: "The results of this Phase 1/2 study demonstrate the safety and tolerability of uproleselan in combination with an intensive salvage chemotherapeutic regimen. The reported response rates and survival outcomes are superior to what has been seen with chemotherapy alone in similar relapsed/refractory AML patient populations. In particular, the MRD negative rate of 69 percent in the relapsed/refractory cohort is unprecedented in producing a high proportion of patients who underwent a successful transplant. We are confident that our ongoing Phase 3 randomized trial will confirm the efficacy seen in the Phase 1/2 study and will help to establish uproleselan in combination with intensive chemotherapy as the new standard of care in relapsed/refractory AML."

ShowHide Related Items >><<
GLYC GlycoMimetics
$2.29 /

+0.07 (+3.15%)

GLYC GlycoMimetics
$2.29 /

+0.07 (+3.15%)

07/12/21 Roth Capital
GlycoMimetics testing Upro + VenAza combo in AML, says Roth Capital
05/03/21 Stifel
GlycoMimetics price target lowered to $8 from $9 at Stifel
03/02/21 Roth Capital
GlycoMimetics has near-term opportunity with Uproleselan, says Roth Captial
12/08/20 Roth Capital
GlycoMimetics price target raised to $15 from $9 at Roth Capital
GLYC GlycoMimetics
$2.29 /

+0.07 (+3.15%)

Conference/Events
GlycoMimetics participates in a webinar with Roth Capital » 13:55
09/22/21
09/22
13:55
09/22/21
13:55
GLYC

GlycoMimetics

$2.22 /

+ (+0.00%)

Webinar will be held on…

Webinar will be held on September 22 at 2 pm.Webcast Link

ShowHide Related Items >><<
GLYC GlycoMimetics
$2.22 /

+ (+0.00%)

GLYC GlycoMimetics
$2.22 /

+ (+0.00%)

07/12/21 Roth Capital
GlycoMimetics testing Upro + VenAza combo in AML, says Roth Capital
05/03/21 Stifel
GlycoMimetics price target lowered to $8 from $9 at Stifel
03/02/21 Roth Capital
GlycoMimetics has near-term opportunity with Uproleselan, says Roth Captial
12/08/20 Roth Capital
GlycoMimetics price target raised to $15 from $9 at Roth Capital
GLYC GlycoMimetics
$2.22 /

+ (+0.00%)

Conference/Events
GlycoMimetics participates in a webinar with Roth Capital » 09:31
09/22/21
09/22
09:31
09/22/21
09:31
GLYC

GlycoMimetics

$2.22 /

+0.11 (+5.21%)

Webinar will be held on…

Webinar will be held on September 22 at 2 pm.Webcast Link

ShowHide Related Items >><<
GLYC GlycoMimetics
$2.22 /

+0.11 (+5.21%)

GLYC GlycoMimetics
$2.22 /

+0.11 (+5.21%)

07/12/21 Roth Capital
GlycoMimetics testing Upro + VenAza combo in AML, says Roth Capital
05/03/21 Stifel
GlycoMimetics price target lowered to $8 from $9 at Stifel
03/02/21 Roth Capital
GlycoMimetics has near-term opportunity with Uproleselan, says Roth Captial
12/08/20 Roth Capital
GlycoMimetics price target raised to $15 from $9 at Roth Capital
GLYC GlycoMimetics
$2.22 /

+0.11 (+5.21%)

Over a month ago
Earnings
GlycoMimetics reports Q2 EPS (28c), consensus (31c) » 07:58
08/05/21
08/05
07:58
08/05/21
07:58
GLYC

GlycoMimetics

$1.98 /

-0.05 (-2.46%)

Cash position: As of June…

Cash position: As of June 30 GlycoMimetics had cash and cash equivalents of $118.9M as compared to $137Mn as of December 31, 2020. "There are now six trials underway evaluating our lead clinical candidate, uproleselan, including three registration trials and three ISTs, which we anticipate will provide clinical data flow beginning in 2022. Importantly, recruitment rates in both our Company-sponsored Phase 3 trial and the National Cancer Institute's Phase 2 portion of the Phase 2/3 trial support our expectation that enrollment in both studies can be completed by the end of this year. The support of clinicians who are enrolling patients in our global studies, and now the new ISTs, has made it possible to broaden the scope of our uproleselan clinical research to address unmet needs in AML and beyond," commented Chief Executive Officer Rachel King.

ShowHide Related Items >><<
GLYC GlycoMimetics
$1.98 /

-0.05 (-2.46%)

GLYC GlycoMimetics
$1.98 /

-0.05 (-2.46%)

07/12/21 Roth Capital
GlycoMimetics testing Upro + VenAza combo in AML, says Roth Capital
05/03/21 Stifel
GlycoMimetics price target lowered to $8 from $9 at Stifel
03/02/21 Roth Capital
GlycoMimetics has near-term opportunity with Uproleselan, says Roth Captial
12/08/20 Roth Capital
GlycoMimetics price target raised to $15 from $9 at Roth Capital
GLYC GlycoMimetics
$1.98 /

-0.05 (-2.46%)

Hot Stocks
GlycoMimetics says clinicians treated 1st patient in uprolesela Phase 1b/2 study » 09:08
07/22/21
07/22
09:08
07/22/21
09:08
GLYC

GlycoMimetics

$2.18 /

+0.09 (+4.31%)

GlycoMimetics announced…

GlycoMimetics announced that clinicians have treated the first patient in a Phase 1b/2 study evaluating the company's lead drug candidate, uproleselan, added to cladribine plus low dose cytarabine, LDAC, in patients with treated secondary AML, ts-AML. The investigator-sponsored trial is being led by Tapan Kadia, M.D., associate professor of Leukemia at The University of Texas MD Anderson Cancer Center. According to Eric Feldman, M.D., GlycoMimetics' Chief Medical Officer, "Patients with treated secondary AML have an extremely poor prognosis. Despite new drug approvals in the field, subgroups of patients with limited options still exist, especially those whose disease has progressed following treatment with a hypomethylating agent. Our previous preclinical and clinical research supports the potential for these patients to benefit from the addition of uproleselan. If the new study demonstrates that targeting E-selectin with uproleselan could help to overcome resistance to other therapies, this would be a significant achievement that underscores the broad potential of our drug candidate."

ShowHide Related Items >><<
GLYC GlycoMimetics
$2.18 /

+0.09 (+4.31%)

GLYC GlycoMimetics
$2.18 /

+0.09 (+4.31%)

07/12/21 Roth Capital
GlycoMimetics testing Upro + VenAza combo in AML, says Roth Capital
05/03/21 Stifel
GlycoMimetics price target lowered to $8 from $9 at Stifel
03/02/21 Roth Capital
GlycoMimetics has near-term opportunity with Uproleselan, says Roth Captial
12/08/20 Roth Capital
GlycoMimetics price target raised to $15 from $9 at Roth Capital
GLYC GlycoMimetics
$2.18 /

+0.09 (+4.31%)

Over a quarter ago
Recommendations
GlycoMimetics testing Upro + VenAza combo in AML, says Roth Capital » 13:16
07/12/21
07/12
13:16
07/12/21
13:16
GLYC

GlycoMimetics

$2.18 /

-0.055 (-2.46%)

Roth Capital analyst…

Roth Capital analyst Zegbeh Jallah tells investors in a research note that the first patient had been dosed in GlycoMimetics's Phase 2 study evaluating the use of Uproleselan in combination with Venetoclax and Azacitidine in treatment-naive, unfit AML. Strong preclinical data support the use of Upro to overcome Venetoclax-resistance, and the triple combination may improve survival in AML, Jallah says. She made no change to her Buy rating or $15 price target.

ShowHide Related Items >><<
GLYC GlycoMimetics
$2.18 /

-0.055 (-2.46%)

GLYC GlycoMimetics
$2.18 /

-0.055 (-2.46%)

05/03/21 Stifel
GlycoMimetics price target lowered to $8 from $9 at Stifel
03/02/21 Roth Capital
GlycoMimetics has near-term opportunity with Uproleselan, says Roth Captial
12/08/20 Roth Capital
GlycoMimetics price target raised to $15 from $9 at Roth Capital
12/07/20 Roth Capital
Roth boosts GlycoMimetics target to $15 after 'game-changing data'
GLYC GlycoMimetics
$2.18 /

-0.055 (-2.46%)

Hot Stocks
GlycoMimetics starts trial of uproleselan combo with venetoclax and azacitidine » 09:09
07/12/21
07/12
09:09
07/12/21
09:09
GLYC

GlycoMimetics

$2.24 /

+0.075 (+3.47%)

GlycoMimetics announced …

GlycoMimetics announced that clinicians at University of California Davis Comprehensive Cancer Center initiated dosing of the first patient in a clinical study of uproleselan combined with venetoclax and azacitidine for the treatment of older or unfit patients with treatment-naive acute myeloid leukemia. AML. Brian A. Jonas, MD, PhD, Davis Division of Hematology/Oncology, is the clinical trial's principal investigator. According to Eric Feldman, MD, GlycoMimetics' Chief Medical Officer, "While the field has seen strong uptake on venetoclax paired with a hypomethylating agent , HMA, in the frontline unfit AML setting, the depth and durability of responses, particularly in patients with adverse risk biology, has been somewhat less than optimal. In this setting, there remains a significant unmet need, and we know that environment-mediated drug resistance , driven by E-selectin, contributes to HMA/venetoclax resistance. If the study shows that E-selectin antagonism with uproleselan improves minimal residual disease MRD negative response rates, this would be an important step forward that underscores the foundational opportunities for uproleselan across the broad spectrum of patients treated for AML."

ShowHide Related Items >><<
GLYC GlycoMimetics
$2.24 /

+0.075 (+3.47%)

GLYC GlycoMimetics
$2.24 /

+0.075 (+3.47%)

05/03/21 Stifel
GlycoMimetics price target lowered to $8 from $9 at Stifel
03/02/21 Roth Capital
GlycoMimetics has near-term opportunity with Uproleselan, says Roth Captial
12/08/20 Roth Capital
GlycoMimetics price target raised to $15 from $9 at Roth Capital
12/07/20 Roth Capital
Roth boosts GlycoMimetics target to $15 after 'game-changing data'
GLYC GlycoMimetics
$2.24 /

+0.075 (+3.47%)

Hot Stocks
GlycoMimetics doses first patient in uproleselan trial » 09:04
05/26/21
05/26
09:04
05/26/21
09:04
GLYC

GlycoMimetics

$2.28 /

-0.125 (-5.21%)

GlycoMimetics announced…

GlycoMimetics announced that clinicians at Washington University School of Medicine in St. Louis have dosed the first patient in an investigator-sponsored trial, or IST, evaluating uproleselan as a prophylactic agent to reduce gastrointestinal, or GI, toxicities associated with high-dose melphalan in autologous hematopoietic cell transplantation for multiple myeloma.

ShowHide Related Items >><<
GLYC GlycoMimetics
$2.28 /

-0.125 (-5.21%)

GLYC GlycoMimetics
$2.28 /

-0.125 (-5.21%)

05/03/21 Stifel
GlycoMimetics price target lowered to $8 from $9 at Stifel
03/02/21 Roth Capital
GlycoMimetics has near-term opportunity with Uproleselan, says Roth Captial
12/08/20 Roth Capital
GlycoMimetics price target raised to $15 from $9 at Roth Capital
12/07/20 Roth Capital
Roth boosts GlycoMimetics target to $15 after 'game-changing data'
GLYC GlycoMimetics
$2.28 /

-0.125 (-5.21%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.